Last reviewed · How we verify

PENPULIMAB-KCQX

AKESO BIOPHARMA · FDA-approved approved Quality 6/100

PENPULIMAB-KCQX is a drug developed by AKESO BIOPHARMA. It is currently FDA-approved.

At a glance

Generic namePENPULIMAB-KCQX
SponsorAKESO BIOPHARMA
Therapeutic areaOther
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

Serious adverse events

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about PENPULIMAB-KCQX

What is PENPULIMAB-KCQX?

PENPULIMAB-KCQX is a pharmaceutical drug developed by AKESO BIOPHARMA.

Who makes PENPULIMAB-KCQX?

PENPULIMAB-KCQX is developed and marketed by AKESO BIOPHARMA (see full AKESO BIOPHARMA pipeline at /company/akeso-biopharma).

What development phase is PENPULIMAB-KCQX in?

PENPULIMAB-KCQX is FDA-approved (marketed).

What are the side effects of PENPULIMAB-KCQX?

Common side effects of PENPULIMAB-KCQX include Nausea, Vomiting, Hypothyroidism, Constipation, Decreased appetite, Decreased weight. Serious adverse events: Decreased lymphocytes (Grade 3-4), Decreased neutrophils (Grade 3-4), Decreased white blood cells (Grade 3-4), Decreased hemoglobin (Grade 3-4).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing